After 8 weeks, in CHD 1 and CHD 2, total cholesterol: 268.1 ± 30.2 mg/dL 248.6 ± 29.2 mg/dL () There was no significant difference between CHD 1 and CHD 2 groups Atorvastatin was superior to 600 mg or 1200 mg CHD
33 hyperlipidemia patients Case-control, open-label study
CHD: 600 mg/day Atorvastatin: 10 mg/day for 8 weeks
After 8 weeks, in CHD group, total cholesterol: 269.5 ± 21.3 mg/dL 246.9 ± 23.7 mg/dL (), LDL cholesterol: 171.2 ± 29.8 mg/dL 155.4 ± 26.5 mg/dL () CHD was superior to historical controls using diet therapy or placebo Atorvastatin was superior to 600 mg CHD
Complete follow-up patients (): 3 patients (4.1%) experienced stroke recurrence Lost to follow-up/dropped-out patients (): among 85, 54 patients were included in the final analysis 8 patients (9.4%) had stroke recurrence OR of CHD for stroke recurrence (versus lost to follow-up): 0.12 times
356 ischemic stroke patients Case-control, open-label study
CHD: 600 mg/day Antiplatelet: antiplatelet agent therapy for 2 years
In CHD group, recurrence occurred in 3 subjects (2.0%) In antiplatelet group, recurrence occurred in 17 subjects (8.2%) OR of CHD for stroke recurrence (versus antiplatelet group): 0.208 times